drugset / Trial / NCT03937609

TITRATE (inducTIon for acuTe ulceRATivE Colitis)

NCT03937609

RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study is to investigate whether intensive, personalized IFX dosing by using a pharmacokinetics driven dashboard system during the induction phase in patients with acute severe UC leads to increased treatment success (as defined by clinical and endoscopic response at week 6) as compared to the standard dosing.

Timeline

Start
2019-09-04
Primary completion
2024-12-15
Completion
2024-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Infliximab Monoclonal antibody 5 mg/kg Intravenous

Indications